Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • LinkedIn
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Arteriosclerosis, Thrombosis, and Vascular Biology

  • My alerts
  • Sign In
  • Join

  • Facebook
  • LinkedIn
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Vascular Biology

Acute and Chronic Smooth Muscle Cell Apoptosis After Mechanical Vascular Injury Can Occur Independently of the Fas-Death Pathway

Masataka Sata, Seiryo Sugiura, Masao Yoshizumi, Yasuyoshi Ouchi, Yasunobu Hirata, Ryozo Nagai
Download PDF
https://doi.org/10.1161/hq1201.098946
Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1733-1737
Originally published November 1, 2001
Masataka Sata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seiryo Sugiura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masao Yoshizumi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuyoshi Ouchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasunobu Hirata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryozo Nagai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Vascular smooth muscle cell (VSMC) apoptosis has been demonstrated in vascular lesions, such as atherosclerotic and postangioplasty restenotic lesions. Balloon injury also induces VSMC apoptosis. Fas is a death factor that mediates apoptosis when it is activated by its ligand, FasL. Fas-mediated apoptosis was found to be implicated in the pathogenesis of vascular diseases in which Fas/FasL expression was detected. We investigated whether the Fas/FasL interaction mediated acute and chronic VSMC apoptosis and lesion formation in a vascular injury model that may resemble balloon angioplasty. A large spring wire was inserted into the femoral artery of C3H/HeJ (wild-type), C3H-gld (Fas ligand−/−), and C3H-lpr (Fas−/−) mice. The wire was left in place for 1 minute to denude and expand the artery. Massive apoptosis was observed in medial VSMCs from 1 to 7 hours later. There was no difference in the number of apoptotic cells among the 3 groups of mice 4 hours after injury. At 4 weeks, the injured arteries presented signs of concentric neointimal hyperplasia composed exclusively of VSMCs. There was no difference in the degree of neointima hyperplasia (intima/media ratios were as follows: wild type 1.4±0.3, gld 1.0±0.2, and lpr 1.3±0.2) or in the number of apoptotic nuclei among the 3 groups. These findings suggest the existence of other signaling pathways for acute and chronic VSMC apoptosis, at least that induced by mechanical vascular injury.

  • Fas
  • apoptosis
  • balloon injury
  • smooth muscle cells
  • intima

Vascular smooth muscle cell (VSMC) apoptosis has been demonstrated in atherosclerosis and in restenotic lesions after angioplasty.1,2 In animal models of balloon vascular injury, medial VSMC apoptosis and subsequent cell loss were observed early after the injury.3,4 However, the molecular mechanisms of vascular cell apoptosis remain to be elucidated,5,6 and the role of smooth muscle cell apoptosis in vascular remodeling is still a matter of controversy.7–10 It has been postulated that vascular cell apoptosis plays a role in the development of vascular lesions,7–10 because exuberant balloon-induced apoptosis results in enhanced neointimal formation.11 In contrast, it has also been proposed that VSMC apoptosis prevents proliferative vascular disease, because forced induction of VSMC apoptosis by gene modification results in a reduction of vascular lesions.12–15

Fas is a death receptor that transmits apoptosis-inducing signals when activated by its ligand (FasL).16 The Fas/FasL system was first identified in the immune system.17,18 However, at present, there is a large body of evidence indicating that the Fas/FasL interaction controls cell death in a wide variety of cell types under physiological and pathological conditions.17,19–24 Cultured VSMCs express abundant Fas on their surface and undergo apoptosis when stimulated by membrane-bound FasL.12,25 Fas was found to be expressed on apoptotic cells in atherosclerotic lesions,7 and it has been proposed that Fas-mediated apoptosis might be involved in the pathogenesis of atherosclerosis.7,26,27

For a better understanding of the pathogenesis of vascular diseases, genetically modified mice have been used.28 Significant neointima-like hyperplasia was noted in several models of vascular injury prepared according to the perivascular approach.29–31 However, in no mouse model was medial cell apoptosis (which plays a pivotal role in vascular remodeling after balloon angioplasty) induced rapidly after the injury.3,4,11 We recently developed a new mouse model of vascular injury, which may resemble the balloon angioplasty model.32 This vascular injury results in medial smooth muscle cell apoptosis after 1 to 7 hours and marked enlargement of the lumen, followed by robust VSMC proliferation and an intimal lesion.32 The neointima continues to grow for 3 weeks; thereafter, no significant change in the size of the neointima is observed. Neointimal hyperplasia is exclusively composed of α-smooth muscle actin–positive cells.32

In the present study, we took advantage of mouse genetics to study the potential involvement of the Fas/FasL system in acute and chronic VSMC apoptosis and in the development of vascular lesions. We induced endovascular injury in wild-type, gld (Fas ligand−/−), and lpr (Fas−/−) mice. There was no significant difference in the number of acute and chronic apoptotic cells or in the size of neointimal hyperplasia among the 3 groups. These results suggest the existence of a Fas-independent pathway that mediates acute and chronic smooth muscle cell apoptosis, at least in response to mechanical overexpansion of the artery.

Methods

Animals

Eight-week-old male C3H/HeJ (wild-type), C3H-gld (FasL−/−), and C3H-lpr (Fas−/−) mice were purchased from Japan SLC, Inc (Shizuoka, Japan), kept in microisolator cages under a 12-hour day-night cycle, and fed regular chow. For all surgical procedures, the mice were anesthetized by intraperitoneal injection of 50 mg/kg Nembutal (Abbott Laboratories) diluted in 0.9% sodium chloride solution. All procedures involving experimental animals were performed in accordance with protocols approved by institutional guidelines for animal care of The University of Tokyo and complied with the Guide for the Care and Use of Laboratory Animals (NIH publication No. 86-23, revised in 1985).

Mouse Femoral Injury Model

Transluminal mechanical injury of the femoral artery was induced by inserting a large wire, as previously described.32 A copy of the tutorial video of the surgical procedure can be obtained by request to M.S., or the video can be viewed online at http://plaza.umin.ac.jp/∼msata/. Briefly, either the left or right femoral artery was exposed by blunt dissection. The femoral artery and vein were looped together proximally and distally with 6-0 silk suture (Natsume Co) for temporary vascular control during the procedure. A straight spring wire (0.38-mm diameter, No. C-SF-15-15, Cook) was carefully inserted into the femoral artery toward the iliac artery via a small branch between the rectus femoris and vastus medialis muscles. The wire was left in place for 1 minute to denude and dilate the artery. Then, the wire was removed, and the silk suture at the proximal portion of the muscular branch artery was secured. Blood flow in the femoral artery was restored by releasing the sutures placed in the proximal and distal femoral portions. The skin incision was closed with a 5-0 silk suture (Natsume Co). The mice were euthanized by intraperitoneal administration of an overdose of Nembutal. Soon after they died, the mice were perfused at a constant pressure via the left ventricle with 0.9% NaCl solution, followed by perfusion fixation in freshly depolymerized 4% paraformaldehyde in PBS (pH 7.4). The femoral artery was carefully excised, further fixed in 4% paraformaldehyde overnight at 4°C, and embedded in paraffin.

Injection of Anti-Fas Antibody

Agonistic anti-Fas antibody (clone Jo2) was purchased from PharMingen.33 The antibody was diluted in PBS and administered intravenously to 8-week-old male C3H/HeJ and C3H-lpr (Fas−/−) mice through the tail vein at 0.5 μg/g. The liver tissues were removed at death, fixed with 4% paraformaldehyde in PBS (pH 7.4), and embedded in paraffin. Three hours after the injection, surviving mice were euthanized by intraperitoneal administration of an overdose of Nembutal, after which the liver tissues were excised. Paraffin-embedded sections were stained with hematoxylin and eosin.

Morphometric Analysis

Cross sections (5 μm) were deparaffinized, stained with hematoxylin and eosin, and mounted with mounting media (Mount Quick, Daido). The image was digitized by a Fujix Digital Camera (HC-300/OL, Fujifilm Co) on a Provis AX80 microscope (Olympus). Morphometric analysis was performed by using software for image analysis (LIA32 for Windows 95, version 0.372, Kazukiyo Yamamoto) on a PC computer (Presario 2295, Compaq). All data are expressed as the mean±SEM.

Staining by TdT-Mediated dUTP Nick End-Labeling

The 4% paraformaldehyde–fixed sections (5 μm) were deparaffinized and rehydrated. The tissue was then treated with 20 μg/mL proteinase K for 30 minutes. Terminal deoxynucleotidyl transferase (TdT) enzyme and fluorescein-dUTP were added to the tissue sections in accordance with the instructions provided by the manufacturer (In Situ Death Detection Kit, Roche Molecular Biochemicals). Nuclei were counterstained with Hoechst 33258 (Sigma Chemical Co) and mounted with Vectashield mounting media (Vector Laboratories, Inc). Specimens were examined and photographed by using a Provis AX80 microscope (Olympus) equipped with an epifluorescence optical lens.

Immunohistochemistry

Paraffin-embedded sections (5 μm thick) were deparaffinized and blocked with 1% rabbit serum. Endothelial cells, T lymphocytes, polymorphonuclear cells, and macrophages were revealed by immunostaining with anti-CD31 antibody (clone MEC13.3, PharMingen), anti-CD3ε hamster monoclonal antibody (Santa Cruz Biotechnology), anti-CD11b monoclonal antibody (clone M1/70, Serotec), and anti-F4/80 monoclonal antibody (clone A3-1, Serotec), respectively, followed by the avidin-biotin complex technique and Vector Red substrate (Vector Laboratories, Inc). Smooth muscle cells were identified by immunostaining with an alkaline phosphatase–conjugated monoclonal antibody to α-smooth muscle actin (clone 1A4, Sigma). Sections were counterstained with hematoxylin.

Statistical Analysis

All results are expressed as the mean±SEM The means were statistically compared by ANOVA, followed by the Student t test. A value of P<0.05 was considered statistically significant.

Results

Rapid Onset of Medial Cell Apoptosis After Mechanical Endovascular Injury in FasL- or Fas-Deficient Mice

A large spring wire was inserted into the femoral artery for 1 minute to denude and expand the artery (wire/lumen ratio 1.9±0.2). As reported for balloon injury models in rat and rabbit arteries,3 acute expansion of the mouse femoral artery induced apoptosis in a large number of medial smooth muscle cells, as determined by the TdT-mediated dUTP nick-end labeling (TUNEL) technique (Figure 1A).32 Massive apoptosis was detected from 1 to 6 hours after injury. At 17 hours, the cellularity of the media declined dramatically, and a few TUNEL-positive cells were detected in the media.32

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Wire-induced injury causes medial cell apoptosis in FasL- and Fas-deficient mice at 4 hours after injury. A large spring wire was inserted into the femoral artery of C3H/HeJ (wild-type), C3H-gld (FasL−/−), and C3H-lpr (Fas−/−) mice. The wire was left in place for 1 minute to denude and expand the artery. Four hours after injury, the injured artery was perfusion-fixed with 4% paraformaldehyde and carefully excised. A, Total nuclei and apoptotic nuclei were stained by use of Hoechst 33258 (top, blue) and by the TUNEL technique (bottom, green), respectively. B, The number of TUNEL-positive nuclei were counted and expressed as a percentage of the total number of nuclei (n=4 per group).

At 4 hours after injury, a similar frequency of apoptosis was detected in wild-type, gld (FasL−/−), and lpr (Fas−/−) mice. There was no significant difference in the number of apoptotic cells among the 3 groups of mice (Figure 1B), indicating that the Fas/FasL system was not involved in VSMC apoptosis induced by vascular injury.

Development of Lesions in FasL- or Fas-Deficient Mice

Four weeks after the injury, a concentric neointimal lesion was found where the large wire had been placed in all mice examined (Figure 2).32 FasL- and Fas-deficient mice developed lesions similar to those developed by wild-type mice (n=6 per group, Figure 2). There was no significant difference in the degree of the neointima (intima/media area ratio was as follows: wild type 1.4 ±0.3, gld 1.0±0.2, and lpr 1.3±0.2) or in the vessel size (circumference of external elastic lamina was as follows: wild type 1.00±0.08 mm, gld 1.07±0.08 mm, and lpr 1.07±0.05 mm) among the 3 groups. .

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Neointimal formation in wild-type, gld (FasL−/−), and lpr (Fas−/−) mice 4 weeks after the injury. The injured femoral artery of C3H, C3H-gld, and C3H-lpr mice was perfusion-fixed 4 weeks after the injury. A, Paraffin-embedded sections were deparaffinized and stained with hematoxylin and eosin. Arrows indicate the internal elastic lamina. Bar=100 μm. B, The digitized images were analyzed morphometrically by using software for image analysis. The intima/media area ratio was calculated. All data are expressed as the mean±SEM (n=6 per group). C, The circumference of the external elastic lamina (EEL) was measured to evaluate the vessel size. All data are expressed as the mean±SEM (n=6 per group).

The neointima was exclusively composed of smooth muscle cells in wild-type, gld, and lpr mice, as determined by immunostaining for α-smooth muscle actin (Figure 3). In all mice, the luminal side of the intima was almost completely reendothelialized at 4 weeks, as determined by anti-CD31 staining (Figure 3). No capillary formation was detected in the intima, excluding the possibility that neointimal formation had resulted from recanalized thrombosis. Macrophages were detected in the adventitia and occasionally in the intima, as determined by immunostaining for F4/80. Macrophage accumulation in the adventitia was more prominent in gld and lpr mice than in wild-type mice (Figure 3). However, we observed no macrophage infiltration in the media. Polymorphonuclear cells and T lymphocytes were seldom detected in the intima (data not shown).

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Characterization of neointimal lesions in wild-type, gld (FasL−/−), and lpr (Fas−/−) mice. Paraffin-embedded sections harvested 4 weeks after the injury were deparaffinized and stained with specific antibodies to detect endothelial cells (CD31), macrophages (F4/80 [Mφ]), and smooth muscle cells (α-smooth muscle actin) by using the avidin-biotin complex technique and Vector Red as the substrate. The sections were counterstained with hematoxylin. The neointima was observed to be exclusively composed of smooth muscle cells. The luminal side was almost completely reendothelialized. Macrophages were detected in the adventitia and occasionally in the neointima. The accumulation of macrophages in the adventitia was more prominent in gld and lpr mice than in wild-type mice.

Chronic VSMC Apoptosis in the Vascular Lesion in the Absence of FasL/Fas Interaction

TUNEL staining revealed that at 4 weeks after injury, a small fraction of the VSMCs was undergoing apoptotic cell death in the neointima as well as in the media (Figure 4). The frequency of apoptosis in the chronic lesions was markedly smaller than that observed 4 hours after the wire injury. The number of apoptotic cells in gld (FasL−/−) or lpr (Fas−/−) mice was not significantly different from that found in wild-type mice, indicating that a Fas-independent pathway mediates VSMC apoptosis in the vascular lesions induced by acute mechanical injury (Table). .

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4. VSMC apoptosis in chronic vascular lesions in FasL- or Fas-deficient mice. The injured artery was perfusion-fixed with 4% paraformaldehyde and excised carefully 4 weeks after the vascular injury was induced. Paraffin-embedded cross sections (5 μm) were stained by use of Hoechst 33258 (blue) to detect total chromatin and by use of the TUNEL method (green) to detect fragmented chromatin. Arrows indicate the apoptotic nuclei in the neointima and the media.

View this table:
  • View inline
  • View popup
Table 1.

Proportion of Apoptotic Cells in Neointima and Media 4 wk After Vascular Injury

Lack of Fas-Mediated Apoptosis in Fas-Deficient Mice

To demonstrate lack of Fas-mediated apoptosis in lpr mice, wild-type mice and lpr mice were challenged with an agonistic anti-Fas antibody.33 Consistent with the results of a previous report,33 the present study found that intravenous injection of the anti-Fas antibody killed all wild-type mice (n=3) within 3 hours, whereas no lpr mouse died. Histological examination revealed fulminant liver injury with diffuse hemorrhage and massive apoptosis of hepatocytes in the liver of wild-type mice, whereas the liver of the lpr mice appeared intact (data not shown). These findings demonstrate that the lpr mice used in the present study were in fact deficient in Fas-mediated apoptosis.

Discussion

In the present study, we evaluated the potential involvement of Fas-mediated signaling in the pathogenesis of proliferative vascular diseases by using a new mouse model of arterial injury that may resemble the balloon angioplasty. There was no significant difference between wild-type mice and mice deficient for Fas or FasL in the number of apoptotic medial cells 4 hours after injury, in the degree of neointimal hyperplasia 4 weeks after injury, or in the number of apoptotic VSMCs in chronic lesions. Our findings provide a crucial insight into the controversial role of Fas-mediated signaling in apoptosis, inflammation, and proliferation in the vessel wall.7,26,27,34

Numerous studies have shown that Fas is implicated in VSMC apoptosis in vascular lesions.7,26,27,34 VSMCs abundantly express Fas,12,25 whose expression is regulated by cytokines7,25 and a tumor suppressor gene, p53.34 Fas expression was also identified on apoptotic VSMCs in human atherosclerotic plaques.7,8 Our results indicate the existence of other molecular pathways that may mediate acute and chronic VSMC apoptosis, at least in lesions induced by the mechanical overexpansion of the artery.

It has been suggested that Fas-mediated signaling contributes to inflammatory responses in vessel walls and, therefore, may promote atherogenesis.35,36 It has been demonstrated that the activation of Fas in peritoneal exudate cells provokes inflammatory responses by stimulating the release of interleukin-1.35 Overexpression of the Fas-associated death domain protein in VSMCs seeded within balloon-injured rat carotid arteries has been shown to result in chemokine expression and the recruitment of macrophages.36 In the present study, we did not observe any attenuation of inflammatory responses in mice deficient in FasL or Fas after the vascular injury. On the contrary, the accumulation of macrophages in the adventitia was more pronounced in FasL−/− and Fas−/− mice. Moreover, it is well known that Fas-deficient mice spontaneously develop generalized degenerative vascular lesions and necrotizing arteritis, which are preceded by infiltration of mononuclear cells and granulocytes.37 More recently, it has been shown that FasL-deficient mice display enhanced macrophage and T-cell infiltration and intima hyperplasia during vascular remodeling in flow-restricted vessels with an intact endothelium.30,38 These data do not support the hypothesis that the Fas/FasL system plays a major role in promoting inflammatory responses in the vessel wall after acute mechanical injury.

Furthermore, it has been suggested that Fas may promote VSMC proliferation in vascular lesions.7,8 Recent studies have demonstrated the role of Fas in the transduction of growth-promoting signals in T cells,39 cardiomyocytes,40 fibroblasts,41 and hepatocytes.42 Schneider et al43 have demonstrated that adenovirus-mediated overexpression of exogenous FasL facilitates VSMC accumulation in hypercholesterolemic rabbits, and they have suggested that vascular expression of FasL may contribute to the progression of atherosclerosis.43 In the present study, mice deficient in Fas or FasL developed neointima hyperplasia similar to that observed in wild-type mice, excluding the possibility that Fas/FasL signaling mediated the VSMC proliferation in the vascular lesions. Moreover, we previously reported that overexpression of FasL induced massive VSMC apoptosis in vitro25 and that adenovirus-mediated gene delivery of FasL into the balloon-injured artery potently limited the size of the lesion.12,14 Taken together, the present findings indicate that endogenous Fas/FasL interaction is not a major determinant for VSMC proliferation, at least in response to mechanical overexpansion of the artery.

In conclusion, the present results indicate that VSMC apoptosis after acute mechanical injury can occur independently of the Fas-death pathway. Fas-independent pathways appear to exist for these phenomena, although further study is required to evaluate the role of the Fas/FasL system in apoptosis, proliferation, and inflammation in other types of vascular diseases, such as atherosclerosis and transplantation-associated arteriosclerosis.

Acknowledgments

This study was supported in part by grant-in-aid 10218202 from the Japanese Ministry of Education, Culture, and Science (Dr Hirata) and by grants from the Japan Heart Foundation, the Tokyo Biochemical Society, the Sankyo Foundation of Life Science, the Japan Foundation of Cardiovascular Research, the Naito Foundation, the Yamanouchi Foundation for Research on Metabolic Disorders, the Japan Research Foundation for Clinical Pharmacology, the NOVARTIS Foundation for the Promotion of Science, the Shionogi Foundation, and the Asahi Glass Foundation (Dr Sata).

Footnotes

  • Received July 27, 2001; revision accepted September 7, 2001.

References

  1. ↵
    Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995; 91: 2703–2711.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Han DKM, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol. 1995; 147: 267–277.
    OpenUrlPubMed
  3. ↵
    Perlman H, Maillard L, Krasinski K, Walsh K, Evidence for the rapid onset of apoptosis in medial smooth muscle cells following balloon injury. Circulation. 1997; 95: 981–987.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Pollman MJ, Hall JL, Gibbons GH, Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury. Circ Res. 1999; 84: 113–121.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Walsh K, Isner JM. Apoptosis in inflammatory-fibroproliferative disorders of the vessel wall. Cardiovasc Res. 2000; 45: 756–765.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res. 2000; 87: 184–188.
    OpenUrlFREE Full Text
  7. ↵
    Geng Y-J, Henderson LE, Levesque EB, Muszynski M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997; 17: 2200–2208.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Cai W, Devaux B, Schaper W, Schaper J. The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis. 1997; 131: 177–186.
    OpenUrlCrossRefPubMed
  9. ↵
    Fukuo K, Inoue T, Morimoto S, Nakahashi T, Yasuda O, Kitano S, Sasada R, Ogihara T. Nitric oxide mediates cytotoxicity and basic fibroblast growth factor release in cultured vascular smooth muscle cells: a possible mechanism of neovascularization in atherosclerotic plaques. J Clin Invest. 1995; 95: 669–676.
    OpenUrlCrossRefPubMed
  10. ↵
    Fukuo K, Nakahashi T, Nomura S, Hata S, Suhara T, Shimizu M, Tamatani M, Morimoto S, Kitamura Y, Ogihara T. Possible participation of Fas-mediated apoptosis in the mechanism of atherosclerosis. Gerontology. 1997; 43: 35–42.
    OpenUrlCrossRefPubMed
  11. ↵
    Rivard A, Luo Z, Perlman H, Fabre J, Nguyen T, Walsh K. Early cell loss following angioplasty results in a disproportionate decrease in gene transfer to the vessel wall. Hum Gene Ther. 1999; 10: 711–721.
    OpenUrlCrossRefPubMed
  12. ↵
    Sata M, Perlman H, Muruve DA, Silver M, Ikebe M, Libermann TA, Oettgen P, Walsh K. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci U S A. 1998; 95: 1213–1217.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Perlman H, Sata M, Krasinski K, Dorai T, Buttyan R, Walsh K. Adenovirus-encoded hammerhead ribozyme to Bcl-2 inhibits neointimal hyperplasia and induces vascular smooth muscle cell apoptosis. Cardiovasc Res. 2000; 45: 570–578.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Luo Z, Sata M, Nguyen T, Kaplan JM, Akita GY, Walsh K. Adenovirus-mediated delivery of Fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation. 1999; 99: 1776–1779.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Pollman MJ, Hall JL, Mann MJ, Zhang L, Gibbons GH. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med. 1998; 4: 222–227.
    OpenUrlCrossRefPubMed
  16. ↵
    Nagata S, Golstein P. The Fas death factor. Science. 1995; 267: 1449–1456.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Nagata S. Apoptosis by death factor. Cell. 1997; 88: 355–365.
    OpenUrlCrossRefPubMed
  18. ↵
    Klas C, Debatin K-M, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol. 1993; 5: 625–630.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Muller M, Strand S, Hug H, Heinemann E-M, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997; 99: 403–413.
    OpenUrlCrossRefPubMed
  20. ↵
    Hueber A-O, Zornig M, Lyon D, Suda T, Nagata S, Evan GI. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 1997; 278: 1305–1309.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Friesen C, Herr I, Krammer H, Debatin K-M. Involvement of the CD95 (Apo-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996; 2: 574–577.
    OpenUrlCrossRefPubMed
  22. ↵
    Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen P. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interaction. Proc Natl Acad Sci U S A. 1997; 94: 5750–5755.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Rehemtulla A, Hamilton CA, Chinnaiyan AM, Dixit VM. Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J Biol Chem. 1997; 272: 25783–25786.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Sata M, Walsh K. Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J Clin Invest. 1998; 102: 1682–1689.
    OpenUrlCrossRefPubMed
  25. ↵
    Sata M, Suhara T, Walsh K. Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand–induced cell death: implications for vascular disease and therapy. Arterioscler Thromb Vasc Biol. 2000; 20: 309–316.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Fukuo K, Hata S, Suhara T, Nakahashi T, Shinto Y, Tsujimoto Y, Morimoto S, Ogihara T. Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension. 1996; 27: 823–826.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Han DKM, Wright ME, Dixit VM, Pruitt R, Soe HS, Lynch DH, Schwartz SM. Evidence for escape of apoptosis by loss of FAS in atherosclerotic plaque smooth muscle cells. Circulation. 1996; 94 (suppl I): I-397. Abstract.
    OpenUrl
  28. ↵
    Faraci FM, Sigmund CD. Vascular biology in genetically altered mice: smaller vessels, bigger insight. Circ Res. 1999; 85: 1214–1225.
    OpenUrlFREE Full Text
  29. ↵
    Carmeliet P, Moons L, Stassen J-M, Mol MD, Bouche A, van den Oord JJ, Kockx M, Collen D. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol. 1997; 150: 761–776.
    OpenUrlPubMed
  30. ↵
    Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol. 1997; 17: 2238–2244.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998; 101: 1225–1232.
    OpenUrlCrossRefPubMed
  32. ↵
    Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S, Aoyagi T, Imai Y, Kurihara H, Kimura K, et al. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol. 2000; 32: 2097–2104.
    OpenUrlCrossRefPubMed
  33. ↵
    Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 1993; 364: 806–809.
    OpenUrlCrossRefPubMed
  34. ↵
    Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 1998; 282: 290–293.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med. 1998; 4: 1287–1792.
    OpenUrlCrossRefPubMed
  36. ↵
    Schaub FJ, Han DK, Liles WC, Adams LD, Coats SA, Ramachandran RK, Seifert RA, Schwartz SM, Bowen-Pope DF. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med;. 2000; 6: 790–796.
    OpenUrlCrossRefPubMed
  37. ↵
    Hewicker M, Trautwein G. Sequential study of vasculitis in MRL mice. Lab Anim. 1987; 21: 335–341.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Sata M, Walsh K. Fas ligand-deficient mice display enhanced leukocyte infiltration and intima hyperplasia in flow restricted vessels. J Mol Cell Cardiol. 2000; 32: 1395–1400.
    OpenUrlCrossRefPubMed
  39. ↵
    Desbarats J, Wade T, Wade WF, Newell MK. Dichotomy between naive and memory CD4(+) T cell responses to Fas engagement. Proc Natl Acad Sci U S A. 1999; 96: 8104–8109.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Nelson DP, Setser E, Hall DG, Schwartz SM, Hewitt T, Klevitsky R, Osinska H, Bellgrau D, Duke RC, Robbins J. Proinflammatory consequences of transgenic fas ligand expression in the heart. J Clin Invest. 2000; 105: 1199–1208.
    OpenUrlCrossRefPubMed
  41. ↵
    Freiberg RA, Spencer DM, Choate KA, Duh HJ, Schreiber SL, Crabtree GR, Khavari PA. Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol. 1997; 108: 215–219.
    OpenUrlCrossRefPubMed
  42. ↵
    Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med. 2000; 6: 920–923.
    OpenUrlCrossRefPubMed
  43. ↵
    Schneider DB, Vassalli G, Wen S, Driscoll RM, Sassani AB, DeYoung MB, Linnemann R, Virmani R, Dichek DA. Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol. 2000; 20: 298–308.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Arteriosclerosis, Thrombosis, and Vascular Biology
November 2001, Volume 21, Issue 11
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Acute and Chronic Smooth Muscle Cell Apoptosis After Mechanical Vascular Injury Can Occur Independently of the Fas-Death Pathway
    Masataka Sata, Seiryo Sugiura, Masao Yoshizumi, Yasuyoshi Ouchi, Yasunobu Hirata and Ryozo Nagai
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1733-1737, originally published November 1, 2001
    https://doi.org/10.1161/hq1201.098946

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Arteriosclerosis, Thrombosis, and Vascular Biology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Acute and Chronic Smooth Muscle Cell Apoptosis After Mechanical Vascular Injury Can Occur Independently of the Fas-Death Pathway
    (Your Name) has sent you a message from Arteriosclerosis, Thrombosis, and Vascular Biology
    (Your Name) thought you would like to see the Arteriosclerosis, Thrombosis, and Vascular Biology web site.
  • Share on Social Media
    Acute and Chronic Smooth Muscle Cell Apoptosis After Mechanical Vascular Injury Can Occur Independently of the Fas-Death Pathway
    Masataka Sata, Seiryo Sugiura, Masao Yoshizumi, Yasuyoshi Ouchi, Yasunobu Hirata and Ryozo Nagai
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1733-1737, originally published November 1, 2001
    https://doi.org/10.1161/hq1201.098946
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Genetics
    • Genetically Altered and Transgenic Models
  • Basic, Translational, and Clinical Research
    • Mechanisms
    • Smooth Muscle Proliferation and Differentiation
    • Cell Signaling/Signal Transduction

Arteriosclerosis, Thrombosis, and Vascular Biology

  • About ATVB
  • Instructions for Authors
  • AHA CME
  • Meeting Abstracts
  • Permissions
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Contact the Editorial Office:
email: atvb@atvb.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured